P-III-NP detection using Atellica and Centaur analyzers on an athletes cohort: comparison and evaluation of hemolysis and storage

Code: 25T02AM

Despite suspected high prevalence of Growth Hormone (GH) doping, detection of GH doping is complex. The indirect method based on two biomarkers increased by GH (growth factor IGF-I and procollagen propeptide P-III-NP) has recently been integrated in the endocrine module from the Athlete biological passport (ABP) to better identify doping with GH using a P-III-NP assay for Centaur Analyzer and IGF-I by top-down mass spectrometry.

However Centaur analyzer and its P-III-NP assay are to be ended soon (2027) and need to be replaced. Siemens proposes a new Atellica analyzer with a test for P-III-NP that is described as highly similar to Centaur results in the normal to pathological range, but this need further confirmation in the athletes population range The aims of the project are to evaluate and confirm this new technical option for P-III-NP quantification in the coming years.

1- Comparison of P-III-NP assays performed on two Siemens analyzers and impact of storage : 200 serum samples previously analyzed for endocrine passport will be reanalyzed for P-III-NP in parallel on Advia Centaur and on the new Siemens analyzer Atellica in order to evaluate the similarity of results in an athletes population.

This will also allow a direct comparison to initial values to confirm storage conditions (-80°C) are appropriate for reanalysis;

2- Impact of various degrees of hemolysis on P-III-NP and IGF-I by adding free hemoglobin to clear sample and checking the quantification of both markers.

These data will help to confirm that the new technical options for P-III-NP detection are fit-for-purpose and will increase knowledge on how variations in quality of serum impact endocrine passport.